16,039
回編集
細編集の要約なし |
細編集の要約なし |
||
24行目: | 24行目: | ||
| legal_US = Schedule III | | legal_US = Schedule III | ||
| legal_UN = Unscheduled | | legal_UN = Unscheduled | ||
| routes_of_administration = Any<ref><pubmed>28657160</pubmed></ref><ref><pubmed> 28339431 </pubmed></ref><ref name="MathewZarate2016"><pubmed>24257811 </pubmed> | | routes_of_administration = Any<ref><pubmed>28657160</pubmed></ref><ref><pubmed> 28339431 </pubmed></ref><ref name="MathewZarate2016"><pubmed>24257811 </pubmed></ref> | ||
| addiction_liability = Low–moderate<ref name="NHM-PCP and ketamine">'''Malenka RC, Nestler EJ, Hyman SE'''<br>Chapter 15: Reinforcement and Addictive Disorders |quote=Phencyclidine (PCP or angel dust) and ketamine (also known as special K) are structurally related drugs... their reinforcing properties and risks related to compulsive abuse<br>edited by Sydor A, Brown RY, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd ed. pp. 374–375 (2009) McGraw-Hill Medical, New York</ref><!--Start widen drugbox--><br /> <!--End widen drugbox--> | | addiction_liability = Low–moderate<ref name="NHM-PCP and ketamine">'''Malenka RC, Nestler EJ, Hyman SE'''<br>Chapter 15: Reinforcement and Addictive Disorders |quote=Phencyclidine (PCP or angel dust) and ketamine (also known as special K) are structurally related drugs... their reinforcing properties and risks related to compulsive abuse<br>edited by Sydor A, Brown RY, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd ed. pp. 374–375 (2009) McGraw-Hill Medical, New York</ref><!--Start widen drugbox--><br /> <!--End widen drugbox--> | ||
| class = [[NMDA receptor antagonists]]; [[General anesthetics]]; [[Dissociative hallucinogen]]s; [[Analgesic]]s; [[Antidepressant]]s | | class = [[NMDA receptor antagonists]]; [[General anesthetics]]; [[Dissociative hallucinogen]]s; [[Analgesic]]s; [[Antidepressant]]s |